```html

Yellow Vision (Xanthopsia) – A Comprehensive Medical Guide

Overview

Xanthopsia (pronounced “zan‑tho‑PEE‑zhuh”) is a type of chromatopsia—a disturbance in color perception—where objects appear tinted yellow or amber. It can range from a faint warmth to a striking, predominantly yellow visual field.

Although the condition is relatively rare, it is encountered in several clinical settings, including ophthalmology, neurology, and psychiatry. Reported prevalence varies because many cases are transient or go unrecognized, but epidemiological data suggest that:

• Up to 5 % of patients receiving high‑dose digoxin develop transient yellow vision (Mayo Clinic, 2023).
• Among individuals with retinal or optic‑nerve disease, xanthopsia may be reported in 1‑3 % of cases (American Academy of Ophthalmology, 2022).

Anyone can be affected, but certain groups are at higher risk:

• Elderly patients on cardiac glycosides (digoxin, ouabain).
• People with cataracts or age‑related macular degeneration (AMD).
• Individuals exposed to certain drugs (e.g., quinine, sildenafil) or toxic substances (lead, thallium).
• Patients with neurological conditions such as migraine aura, temporal lobe epilepsy, or lesions affecting the visual pathway.

Symptoms

Symptoms of xanthopsia may appear suddenly or develop gradually. The following list includes the most common manifestations, with brief explanations for each.

Visual Disturbances

• Yellow or amber tint on all objects, often described as “seeing through a sunrise filter.”
• Reduced contrast sensitivity—difficulty distinguishing fine details, especially between shades of white and gray.
• Glare and halos around lights, particularly at night.
• Difficulty with color discrimination, especially distinguishing blues and greens from yellows.
• Fluctuating intensity—the yellow hue may be more pronounced in bright light and fade in low light.

Associated Neurological or Systemic Signs

• Headache or migraine aura (when xanthopsia is part of a migraine).
• Palpitations, nausea, or visual “floaters” in drug‑induced cases.
• Generalized fatigue or weakness if the underlying cause is systemic (e.g., digoxin toxicity).

Psychological Impact

• Anxiety or fear due to sudden change in vision.
• Difficulty concentrating, especially when work or driving requires accurate color perception.

Causes and Risk Factors

Xanthopsia is not a disease itself; it is a symptom of an underlying condition. Major categories include:

Medication‑Related Causes

• Cardiac glycosides (digoxin, digitoxin) – classic cause; toxicity leads to retinal pigment changes.
• Quinine and related antimalarial drugs – interfere with retinal metabolism.
• Sildenafil (Viagra) and other phosphodiesterase‑5 inhibitors – rare case reports of transient yellow vision.
• Phenothiazine antipsychotics – can cause pigmentary retinal changes.

Ophthalmic Conditions

• Cataract formation – yellowing of the natural lens scatters short‑wavelength light.
• Age‑related macular degeneration – drusen and lipofuscin accumulation produce a amber hue.
• Retinal dystrophies (e.g., Stargardt disease) – accumulation of yellowish lipofuscin.

Neurological Disorders

• Migraine with aura – visual phenomena can include yellow tints.
• Temporal lobe epilepsy – ictal visual phenomena may be chromatic.
• Posterior circulation strokes – affect the visual cortex, occasionally leading to chromatic distortions.

Toxic Exposures

• Heavy metals (lead, thallium) – interfere with photoreceptor function.
• Organic solvents (e.g., toluene) – chronic exposure linked to retinal pigment changes.

Risk Factors

• Age > 60 years (higher prevalence of cataract and AMD).
• Renal insufficiency – reduces clearance of digoxin, increasing toxicity risk.
• Polypharmacy – multiple drugs that may synergistically affect retinal function.
• Genetic predisposition to retinal pigment disorders.

Diagnosis

Diagnosing xanthopsia starts with a thorough history and eye examination, followed by targeted investigations to uncover the root cause.

Clinical Evaluation

• History taking – medication review, recent illnesses, exposure to toxins, and onset pattern.
• Visual acuity testing – to assess any loss of sharpness.
• Color vision testing – Ishihara plates (modified for yellow bias) or Farnsworth‑Munsell 100 Hue test.
• Slit‑lamp examination – evaluates the cornea, lens, and anterior segment for cataracts or deposits.
• Fundus examination – dilated ophthalmoscopy to look for retinal pigment changes, drusen, or optic‑nerve abnormalities.

Ancillary Tests

• Optical Coherence Tomography (OCT) – high‑resolution imaging of retinal layers; can detect macular degeneration or drug‑induced retinal thinning.
• Fundus Autofluorescence (FAF) – highlights lipofuscin accumulation that may cause a yellow hue.
• Electroretinography (ERG) – measures retinal electrical responses; reduced amplitude may indicate drug toxicity.
• Serum drug levels – especially digoxin concentration.
• Blood work – liver/kidney function, heavy‑metal panels.
• Neuroimaging (MRI/CT) – when a neurological cause is suspected (e.g., stroke, tumor).

Diagnostic Criteria (simplified)

A diagnosis of xanthopsia is made when:

1. Patient reports a persistent yellow tint in vision.
2. Objective testing confirms altered color perception.
3. One or more underlying causes are identified through history, examination, or investigations.

Treatment Options

Treatment is fundamentally directed at the underlying etiology. General measures include removal of the offending agent and supportive care.

Medication‑Related Cases

• Discontinue or adjust the offending drug – e.g., lower digoxin dose or switch to an alternative anti‑arrhythmic.
• Digoxin toxicity – administer digoxin‑specific antibody fragments (Digibind) if serum levels are dangerously high or if there are cardiac arrhythmias.
• Monitor serum drug levels until they return to therapeutic range.

Ophthalmic Interventions

• Cataract surgery – removal of a yellowed natural lens and implantation of a clear intra‑ocular lens often resolves the tint.
• Anti‑VEGF injections for neovascular AMD can stabilize the retina, reducing pigmentary changes.
• Low‑vision aids (tinted glasses with a blue filter) may improve contrast for residual symptoms.

Neurological Management

• Migraine prophylaxis (beta‑blockers, topiramate, CGRP antagonists) when migraine aura is the trigger.
• Antiepileptic drugs for patients with seizure‑related visual phenomena.
• Acute stroke care per established guidelines (thrombolysis, thrombectomy) if a vascular event is identified.

Lifestyle and Supportive Measures

• Hydration and proper nutrition to support retinal health (vitamins A, C, E, zinc, lutein, zeaxanthin – supported by AREDS2 study).
• Avoidance of known toxins (lead paint, industrial solvents).
• Regular eye examinations—at least annually for adults > 50 years or sooner if symptoms develop.

Living with Yellow Vision (Xanthopsia)

Even after treatment, some patients may retain a slight yellow cast. Practical strategies can help maintain independence and safety.

• Optimize lighting – use bright, white (5000 K) LEDs to reduce glare and improve contrast.
• Use color‑correcting lenses – blue‑blocking glasses can neutralize the yellow tint for reading or computer work.
• Label medications and household items with large print or tactile markers to compensate for color discrimination difficulties.
• Driving safety – avoid night driving until vision stabilizes; consider a professional driving assessment if visual changes persist.
• Technology aids – smartphone apps that identify colors verbally (e.g., “ColorID”).
• Regular follow‑up with ophthalmology or neurology to monitor progression.

Prevention

Because xanthopsia is usually secondary, prevention focuses on minimizing risk factors.

• Medication vigilance – keep an updated list; ask physicians about visual side effects before starting new drugs.
• Therapeutic drug monitoring – especially for digoxin, lithium, or antimalarials.
• Protect eyes from UV and blue light – wear sunglasses with UV‑400 protection; consider blue‑light filters for screens.
• Manage chronic diseases – control hypertension, diabetes, and hyperlipidemia to reduce retinal vascular disease.
• Healthy diet – foods rich in lutein and zeaxanthin (leafy greens, corn, eggs) support macular health.
• Occupational safety – use proper protective equipment when handling metals or solvents.

Complications

If the underlying cause is not addressed, several complications may arise:

• Permanent retinal damage – drug toxicity or chronic AMD can lead to irreversible visual loss.
• Falls and accidents – reduced contrast and glare increase risk, especially in older adults.
• Psychological distress – persistent visual distortion may cause anxiety, depression, or social withdrawal.
• Cardiac complications – in digoxin toxicity, arrhythmias, heart block, or even sudden cardiac death can occur.

When to Seek Emergency Care

Timely evaluation can prevent permanent damage and address life‑threatening conditions.

---

References (selected):

• Mayo Clinic. “Digoxin Side Effects.” Updated 2023.
• American Academy of Ophthalmology. “Color Vision Deficiencies.” 2022.
• National Eye Institute (NEI). Age‑Related Macular Degeneration Fact Sheet, 2021.
• World Health Organization. “Global Health Estimates: Vision Impairment.” 2022.
• Cleveland Clinic. “Cataract Surgery Risks and Benefits.” 2024.
• AREDS2 Research Group. “Lutein+Zeaxanthin and Visual Function.” JAMA Ophthalmol, 2020.

```